ATE356204T1 - Antisense-zusammensetzungen und verfahren zur behandlung von krebs - Google Patents

Antisense-zusammensetzungen und verfahren zur behandlung von krebs

Info

Publication number
ATE356204T1
ATE356204T1 AT00968807T AT00968807T ATE356204T1 AT E356204 T1 ATE356204 T1 AT E356204T1 AT 00968807 T AT00968807 T AT 00968807T AT 00968807 T AT00968807 T AT 00968807T AT E356204 T1 ATE356204 T1 AT E356204T1
Authority
AT
Austria
Prior art keywords
methods
treating cancer
stem cells
antisense compositions
composition
Prior art date
Application number
AT00968807T
Other languages
English (en)
Inventor
Stephen H Bartelmez
Patrick L Iversen
Original Assignee
Avi Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avi Biopharma Inc filed Critical Avi Biopharma Inc
Application granted granted Critical
Publication of ATE356204T1 publication Critical patent/ATE356204T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/02—Aminoacyltransferases (2.3.2)
    • C12Y203/02013—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00968807T 1999-10-07 2000-10-06 Antisense-zusammensetzungen und verfahren zur behandlung von krebs ATE356204T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15834099P 1999-10-07 1999-10-07

Publications (1)

Publication Number Publication Date
ATE356204T1 true ATE356204T1 (de) 2007-03-15

Family

ID=22567684

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00968807T ATE356204T1 (de) 1999-10-07 2000-10-06 Antisense-zusammensetzungen und verfahren zur behandlung von krebs

Country Status (8)

Country Link
EP (1) EP1228202B1 (de)
JP (1) JP2003511393A (de)
KR (1) KR100695677B1 (de)
AT (1) ATE356204T1 (de)
AU (1) AU784358B2 (de)
CA (1) CA2385220A1 (de)
DE (1) DE60033840D1 (de)
WO (1) WO2001025422A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1224261A1 (de) * 1999-10-07 2002-07-24 Avi Biopharma, Inc. .hämatopoietische stammzellen behandelt mit c-myc-antisensmoleküle und dazugehörende verfahren
GB0118223D0 (en) * 2001-07-26 2001-09-19 Univ Sheffield Stem loop RNA
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
ATE556714T1 (de) 2002-02-01 2012-05-15 Life Technologies Corp Doppelsträngige oligonukleotide
US20040102390A1 (en) * 2002-11-21 2004-05-27 Isis Pharmaceuticals Inc. Modulation of Notch3 expression
US20040101847A1 (en) * 2002-11-22 2004-05-27 Isis Pharmaceuticals Inc. Modulation of Notch2 expression
WO2005021783A2 (en) * 2003-08-30 2005-03-10 Adrian Merlo New use of gain and loss of notch2 function in brain tumors and the new notch2 genetic alterations of the notch2 gene per se
AU2007356840B2 (en) * 2007-07-25 2013-07-18 Alma Mater Studiorum - Universita Di Bologna Pharmaceutical composition and pharmaceutical kit for the treatment of hepatocellular carcinoma
CA2800065A1 (en) 2010-05-21 2011-11-24 Peptimed, Inc. Reagents and methods for treating cancer
BR112013010911A2 (pt) 2010-11-01 2017-05-02 Peptimed Inc composições de um sistema à base de peptídeo para direcionamento para céllas específicas

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL101600A (en) * 1992-04-15 2000-02-29 Yissum Res Dev Co Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
WO2001025422A3 (en) 2001-08-23
AU784358B2 (en) 2006-03-16
CA2385220A1 (en) 2001-04-12
EP1228202A2 (de) 2002-08-07
KR100695677B1 (ko) 2007-03-15
EP1228202B1 (de) 2007-03-07
KR20020064793A (ko) 2002-08-09
DE60033840D1 (de) 2007-04-19
AU7866800A (en) 2001-05-10
WO2001025422A2 (en) 2001-04-12
JP2003511393A (ja) 2003-03-25

Similar Documents

Publication Publication Date Title
ATE265219T1 (de) Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
DK1082410T3 (da) Humane CD45 - og/eller fibroblast mesenchymale stamceller
DE60043229D1 (de) Zusammensetzung zur gefässbeschichtung
DE69937888D1 (de) Verbesserung der herzfunktion durch transplantation mesenchymaler stammzellen
GB9807639D0 (en) Anti-inflammatory agents
ATE535141T1 (de) Verfahren zur modifikation von pflanzlicher biomasse
BR0011197A (pt) Método de tratamento de uma doença autoimunológica em um mamìfero, compreendendo antagonistas que se ligam aos marcadores de superfìcie de células b e artigo de manufatura
TW200712208A (en) Use of adipose tissue-derived stromal cells for chondrocyte differentiation and cartilage repair
GEP20033092B (en) Purine Inhibitors of Cyclin Dependent Kinase 2 and Ik-Aa
ATE356204T1 (de) Antisense-zusammensetzungen und verfahren zur behandlung von krebs
DE60319398D1 (de) Verfahren zur herstellung einer pureezusammensetzung enthaltend eine stabilisierte fruchtmarkzusammensetzung
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
WO2003057849A3 (en) Telomere-encoding synthetic dna nanocircles, and their use for the elongation of telomere repeats
TR200103634T2 (tr) Bitkilerde flavonoidlerin ve fenolik maddelerin miktarını arttırma yöntemi.
DE69931050D1 (de) Brassica-transformation durch teilchenbeschuss
HUP0002903A2 (hu) Növénytranszformációs módszerek
DE69902523D1 (de) Verwendung von erythropoietin zur behandlung von multiple myelom
ATE348876T1 (de) Verfahren zur vermehrung von natürlichen killerzellen
ATE375780T1 (de) Haarbehandlungszusammensetzung
ATE300295T1 (de) Verwendung von baclofen zur behandlung von alkoholismus
WO2008014426A3 (en) Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
ATE524198T1 (de) Verfahren zur einführung von genen in säugetiere
PT1147088E (pt) 6-arilfenantridinas com actividade inibitoria da pde-iv
张宝红 et al. Anther culture and plant regeneration of cotton (Gossypium klotzschianum Anderss)
AU8371501A (en) Manipulation of plant senescence using an MYB gene promoter and cytokinin biosyntyhesis genes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties